Sign in
Stories
BMS Showcases Myeloma Pipeline and Abecma Benefits
Share
Advancements in Cancer Treatment and Mar...
BCMA-Targeted CAR-T Cell Therapy Progres...
Health Innovations: Diagnostics & Profil...
AB-2100 Phase 1/2 Trial Initiated
Advancements in Lymphoma Treatments
Advancing CD70 Targeted Cancer Treatment...
Overview
API
Bristol Myers Squibb presents diverse multiple myeloma pipeline at ASH 2023, showcasing tailored treatment approaches. The company also announces sustained progression-free survival benefit of Abecma in relapsed and refractory multiple myeloma, demonstrating improved durability of responses and safety profile.
Ask a question
How could the planned Phase 2 trial of BMS-986393 contribute to the advancement of treatment options for patients with RRMM exposed to multiple classes of therapy?
How might the diverse multiple myeloma pipeline presented by BMS impact the landscape of personalized treatment approaches for multiple myeloma?
What are the potential implications of the sustained progression-free survival benefit of Abecma on the treatment landscape for relapsed and refractory multiple myeloma?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage